Immunohistochemical labeling for thrombospondin 1. by Harry A. Quigley (695817)

Basic characteristics included in the study. by Juan Gu (288925)

“…A period of 10–20 years since the last birth also showed a decreased risk (OR=0.867; 95% CI:0.747–1.007), whereas more than 20 years since the last birth was associated with an increased risk (OR = 1.304; 95% CI: 1.111–1.530).…”

Publication bias of the risk of all groups. by Juan Gu (288925)

“…A period of 10–20 years since the last birth also showed a decreased risk (OR=0.867; 95% CI:0.747–1.007), whereas more than 20 years since the last birth was associated with an increased risk (OR = 1.304; 95% CI: 1.111–1.530).…”

Study selection process. by Juan Gu (288925)

“…A period of 10–20 years since the last birth also showed a decreased risk (OR=0.867; 95% CI:0.747–1.007), whereas more than 20 years since the last birth was associated with an increased risk (OR = 1.304; 95% CI: 1.111–1.530).…”

Intermittent Heat Shocks Can Reduce Methanogenesis and Increase Generation of Longer-Chain Volatile Fatty Acids in Anaerobic Bioreactors by Hezhou Ding (14242293)

“…The relative abundances of putative chain-elongating bacteria increased and those of syntrophic acetate-forming bacteria decreased when the HSs were applied. Our findings show that intermittent HSs may provide a chemical-free methanogen-specific strategy to improve the production of VFAs, especially longer-chain species.…”

Axonal transport effects, APP labeling with losartan-treated vs water control. by Harry A. Quigley (695817)

Degradation of clots of different ages. by Jan Víteček (11434774)

Fixed Peripapillary Thickness. by Harry A. Quigley (695817)

Experimental study groups and the number of animals within each. by Harry A. Quigley (695817)

Primary antibodies used for histological studies and Immunoblot. by Harry A. Quigley (695817)

Blood pressure data. by Harry A. Quigley (695817)

Axial length and width. by Harry A. Quigley (695817)

The process of selecting participants. by Na Li (6550)

“…Chemotherapy was found to be protective factor for OS (HR = 0.33, 95%CI: 0.30–0.37)/CSS (HR = 0.44, 95%CI: 0.39–0.50) of ovarian cancer patients, while not receiving surgery remained a risk factor. …”

C-indexes for the nomograms. by Na Li (6550)

“…Chemotherapy was found to be protective factor for OS (HR = 0.33, 95%CI: 0.30–0.37)/CSS (HR = 0.44, 95%CI: 0.39–0.50) of ovarian cancer patients, while not receiving surgery remained a risk factor. …”

Multivariable model for percent axon loss. by Harry A. Quigley (695817)

Axon loss by treatment group. by Harry A. Quigley (695817)

Tonolab Calibration. by Harry A. Quigley (695817)

The dependency of thrombolysis on rt-PA concentration. by Jan Víteček (11434774)

Intracellular pH of <i>C</i>. <i>albicans</i> ATCC 90028; FLC-susceptible <i>C</i>. <i>albicans</i> D27and FLC-resistant <i>C</i>. <i>albicans</i> D15.9 with and without the treatm... by Mohammad Irfan (464459)

Pressure—strain estimates in load—unload protocol for losartan and control groups. by Harry A. Quigley (695817)